Noncoding mutations drive persistence of a founder preleukemic clone which initiates late relapse in T-ALL

Abstract T-ALL relapse usually occurs early but can occur much later, which has been suggested to represent a de novo leukemia. However, we conclusively demonstrate late relapse can evolve from a pre-leukemic subclone harbouring a non-coding mutation that evades initial chemotherapy.